01 June 2012
A prospective study on different methods for the treatment of choroidal neovascularization. The efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age-related macular degeneration
Michał S. NowakABCDEF, Piotr JurowskiAD, Andrzej GrzybowskiEF, Roman GośA, Mirosław PastuszkaB, Andrzej KapicaB, Janusz ŚmigielskiCDOI: 10.12659/MSM.882907
Med Sci Monit 2012; 18(6): CR374-380
Abstract
Background: The aim of this study was to compare the efficacy of verteporfin photodynamic therapy (PDT), intravitreal injections of bevacizumab (IVB) and transpupillary thermotherapy (TTT) in patients with neovascular age-related macular degeneration (AMD).
Material/Methods: The study design was a prospective, interventional, comparative case series. Between December 2006 and March 2009, 426 eyes of 426 consecutive patients presenting with neovascular AMD were included into the study. Patients presented with subfoveal CNV predominantly classic, minimally classic, and occult with no classic component; lesion size less than 5000 µm in the greatest linear dimension, and the area of hemorrhages ≤1/3 were randomized to receive either PDT (group I) or IVB (group II) in a 1:1 ratio. Other patients with CNV were included into the group III and received TTT.
Results: One hundred eyes were treated with PDT. Mean baseline logMAR BCVA was 0.62 and final visual acuity decreased to 0.74 (p<0.05, Wilcoxon test); 104 eyes were treated with IVB. Mean baseline BCVA was 0.82 and final visual acuity increased to 0.79 (p>0.05, Wilcoxon test); 222 patients were treated with TTT. Mean baseline BCVA was 1.10 and final visual acuity decreased to 1.15 (p>0.05, Wilcoxon test). Among all eyes the average number of treatment sessions was 2.34 (SD 1.17).
Conclusions: Our study shows that IVB injections had the best efficacy in the improvement of final BCVA. However, both IVB and TTT demonstrated good stabilization of vision. Although after PDT final BCVA was significantly worse from baseline, it may also be beneficial for some patients with neovascular age-related macular degeneration.
Keywords: Photosensitizing Agents - therapeutic use, Porphyrins - therapeutic use, Photochemotherapy, Macular Degeneration - physiopathology, Intravitreal Injections, Hyperthermia, Induced - methods, Demography, Choroidal Neovascularization - physiopathology, Antibodies, Monoclonal, Humanized - therapeutic use, Aged, 80 and over, Prospective Studies, Pupil - drug effects, Visual Acuity - drug effects
Editorial
01 January 2025 : Editorial
Editorial: The Human Cell Atlas. What Is It and Where Could It Take Us?DOI: 10.12659/MSM.947707
Med Sci Monit 2025; 31:e947707
In Press
Clinical Research
Butorphanol Tartrate Nasal Spray for Post-Cesarean Analgesia and Prolactin SecretionMed Sci Monit In Press; DOI: 10.12659/MSM.945224
Database Analysis
Role of the Carhart Effect and Outcomes from Surgery: A Retrospective Study of 532 Patients with Conductive...Med Sci Monit In Press; DOI: 10.12659/MSM.947061
Clinical Research
Factors Affecting Medication Adherence in Middle-Aged and Elderly Patients in China: A Cross-Sectional StudyMed Sci Monit In Press; DOI: 10.12659/MSM.945805
Review article
Characteristics and Associated Risk Factors of Broad Ligament Hernia: A Systematic ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.946710
Most Viewed Current Articles
17 Jan 2024 : Review article 6,963,278
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 700,194
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 23,571
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 18,228
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912